Literature DB >> 2840908

Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin.

L Rossignol1, M Plantavid, H Chap, L Douste-Blazy.   

Abstract

[3H]Pentoxifylline and [3H]propentofylline were taken up by human platelets in a dose-dependent manner probably involving a passive diffusion through the plasma membrane. In vitro, the two drugs were able to inhibit platelet activation induced by thrombin. serotonin secretion was reduced from 57% to 38% and 28% in the presence of 1 mM pentoxifylline and 1 mM propentofylline, respectively. Platelet aggregation was inhibited in the same way. Modifications of [14C]arachidonic acid metabolism in human platelets stimulated by thrombin were then measured in the presence of drugs. Preincubation of platelets with 1 mM pentoxifylline or propentofylline inhibited the production of [14C]arachidonic acid metabolites, without any accumulation of free arachidonic acid, suggesting an action at a step preceding its conversion. Phosphatidylinositol and phosphatidylcholine hydrolysis measured upon thrombin treatment as well as phosphatidic acid production were reduced or suppressed in the presence of the drugs. A dose-dependence study showed that phosphatidylcholine hydrolysis was totally inhibited at 5.10(-4) M propentofylline, while phosphatidic acid formation was reduced by only 40%. Propentofylline was in general more efficient than pentoxifylline in inhibiting events occurring upon thrombin stimulation. Our results suggest that the two methylxanthines inhibit both phospholipase A2 and phospholipase C, the former displaying a greater sensitivity to the two drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840908     DOI: 10.1016/0006-2952(88)90632-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.

Authors:  C Raetsch; J D Jia; G Boigk; M Bauer; E G Hahn; E-O Riecken; D Schuppan
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

3.  Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction.

Authors:  D E Hallahan; S Virudachalam; J Kuchibhotla; D W Kufe; R R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.

Authors:  J Arias-Díaz; E Vara; C García; J L Balibrea
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

5.  Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin.

Authors:  W Pruzanski; D W Wilmore; A Suffredini; G D Martich; A G Hoffman; J L Browning; E Stefanski; B Sternby; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

6.  Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: the effects of dexamethasone, pentoxifylline, iloprost and a polyclonal anti-human IL-1 alpha antibody.

Authors:  R S Heyderman; N J Klein; O A Daramola; M Levin
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.